The invention provides chimeric antigen receptor T (CAR-T) cell compositions for targeting tumor cells. The compositions contain (a) a CAR-T cell having in the extracellular domain of its CAR a catalytic antibody (e.g., a scFv molecule derived from catalytic antibody 38C2), and (b) an adapter compound containing a substrate moiety of the catalytic antibody that is linked to a targeting moiety that specifically recognizes a surface molecule of a target tumor cell. The compositions allow formation of a covalent bond between the catalytic antibody in the CAR and the targeting moiety. The targeting moieties employed in the compositions can be obtained via screening DNA-encoded compound library for specific binding to the target tumor surface molecules. Also provided in the invention are therapeutic methods of using the CAR-T cell compositions of the invention to in the treatment of various tumors of interest.

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

Provided herein are compositions and methods for cancer immunotherapy. In particular, provided herein are compositions and methods for blocking CD6 binding to ligands on cancer cells.

A method for activating or enriching V17.sup.+CD8.sup.+ T cells, comprising contacting a M1 peptide derived from human influenza A virus (M1.sub.58-66) with a population of cells comprising T cells.

The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.

The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.

The technology relates generally to the field of immunology and relates in part to T cell compositions and methods for treating diseases and disorders associated with the presence of tumor cells that express prostate stem cell antigen.

Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, and an amino acid sequence of a light chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 2. The anti-PSMA single-chain antibody is a humanized scFv antibody of PSMA, is more functional in the human body, has better compatibility, and is less prone to be rejected by the immune system. The chimeric antigen receptor has better response effects after specifically bonding to PSMA so that CAR-T cells generate a stronger immune response to tumors, and the chimeric antigen receptor also has better long-term effectiveness than other PSMA chimeric antigen receptors.

The present disclosure provides modified immune cells or precursors thereof (e.g. modified T cells) comprising a chimeric cell surface sialidase or a variant sialidase precursor protein. Compositions and methods of treatment are also provided.

Disclosed are compositions and methods for identifying neoantigens and using neoantigens in the use of treating cancer, as well as autoimmune diseases, where antigens causing tissue destruction.